Consolidated Statements of Changes in Stockholders' Equity - USD ($)		Total	Common Stock	Additional paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2015			1,883,303
Beginning balance at Dec. 31, 2015		$ 518,344,462	$ 18,833	$ 678,171,322	$ (159,845,693)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		(223,522,435)			(223,522,435)
Issuance of shares in connection with Second Lien Loan Agreement (in shares)			16,889,828
Issuance of shares in connection with Second Lien Loan Agreement		17,756,325	$ 168,899	17,587,426
Issuance of shares for private placement, net of issuance costs (in shares)			29,333,318
Issuance of shares for private placement, net of issuance costs		85,700,535	$ 293,333	85,407,202
Reverse stock split adjustment (in shares)	[1]		(32)
Issuance of shares due to vesting of restricted shares (in shares)			410
Issuance of shares due to vesting of restricted shares			$ 4	(4)
Cash used to settle net share equity awards		(2,938)		(2,938)
Stock-based compensation		2,206,690		2,206,690
Ending balance (in shares) at Dec. 31, 2016			48,106,827
Ending balance at Dec. 31, 2016		400,482,639	$ 481,069	783,369,698	(383,368,128)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		(43,796,685)			(43,796,685)
Issuance of shares for private placement, net of issuance costs (in shares)			22,222,223
Issuance of shares for private placement, net of issuance costs		96,030,003	$ 222,222	95,807,781
Issuance of shares due to vesting of restricted shares (in shares)			65,257
Issuance of shares due to vesting of restricted shares		0	$ 653	(653)
Cash used to settle net share equity awards		(289,539)		(289,539)
Stock-based compensation		8,738,615		8,738,615
Ending balance (in shares) at Dec. 31, 2017			70,394,307
Ending balance at Dec. 31, 2017		461,165,033	$ 703,944	887,625,902	(427,164,813)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)		12,574,684			12,574,684
Issuance of shares due to vesting of restricted shares and exercise of options, net of cash received (in shares)			661,093
Issuance of shares due to vesting of restricted shares and exercise of options, net of cash received		4,866	$ 6,611	(1,745)
Cash used to settle net share equity awards		(2,559,104)		(2,559,104)
Stock-based compensation		9,207,480		9,207,480
Ending balance (in shares) at Dec. 31, 2018			71,055,400
Ending balance at Dec. 31, 2018		$ 479,605,849	$ 710,555	$ 894,272,533	$ (415,377,239)

[1] Effective August 5, 2016, the Company completed a 1 for 20 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share (the “Reverse Stock Split”), pursuant to which proportional adjustments were made to the Company’s issued and outstanding common stock and to its common stock underlying stock options and other common stock-based equity grants outstanding immediately prior to the effectiveness of the Reverse Stock Split as well as the applicable exercise price. In addition, proportional adjustments were made to the number of shares of common stock issuable upon exercise of outstanding warrants and to the exercise price of such warrants, pursuant to the terms thereof. No fractional shares were issued in connection with the Reverse Stock Split, and shareholders who would have received a fractional share of common stock in connection with the Reverse Stock Split instead received a cash payment in lieu of such fractional share. The Company also had 3,040,540 outstanding warrants convertible to 152,027 shares of the Company's common stock which will be recorded as equity upon exercise at an exercise price of $556.40 per share. The warrants have a 7 year term and will expire on October 15, 2021.